(Reuters) - Also in 2008, the company may release in the United States cholesterol drugs Simcor and ABT-335, and may release the Xience V drug-coated stent, a mesh tube that injects a drug into open arteries that prevents scarring.
At Friday's close of $55.80, Abbott shares trade at 19.9 times the average analyst forecast for 2007 profit, according to Reuters Estimates.
Read more at Reuters.com Hot Stocks News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment